Vitiligo
Vitiligo
Vitiligo has been, until recently, a rather neglected area in dermatology and medicine. Patients complain about this situation, which has offered avenues to quacks, and has led to the near orphan status of the disease. The apparently, simple and poorly symptomatic presentation of the disease has been a strong disadvantage to its study, as compared to other common chronic skin disorders such as psoriasis and atopic dermatitis. Vitiligo is still considered by doctors as a non disease, a simple aesthetic problem. A good skin-based angle of attack is also lacking because generalized vitiligo is clearly epitomizing the view of skin diseases as simple targets of a systemic unknown dysregulation (diathesis), reflecting the Hippocratic doctrine. This view has mostly restricted vitiligo to the manifestation of an auto-immune diathesis in the past 30 years. Thus, skin events, which are easily detected using skin biospies in most other situations, have not been precisely recorded, with the argument that a clinical diagnosis was sufficient for the management (or most commonly absence of management) of the patient.

This book is an international effort to summarize the information gathered about this disorder at the clinical, pathophysiological and therapeutic levels. Its primary aim is to bridge current knowledge at the clinical and investigative level, to point to the many unsolved issues, and to delineate future priorities for research. Its impetus was also to provide the best guidelines for integrated patient care, which is currently possible at a very limited number of places around the world, especially for surgical procedures.

A striking feature in the vitiligo field was, until recently, the absence of consensus on definitions, nomenclature, and outcome measures. With a group of European dermatologists, who had a strong interest in vitiligo and pigment cell research, we had launched some years ago, the Vitiligo European Task Force (VETF). The VETF has addressed those issues as a priority. This group, joined by other colleagues from the rest of the world also involved in the vitiligo research community, has communicated its experience in this book. We have tried to pilot the editing of the book according to consistent principles based on discussions held at VETF meetings and international IPCC (international pigment cell conference) workshops. However, some areas remain controversial and we have highlighted the existing conflicting issues and uncertainties.

After reviewing the field, much needs to be done. In particular, besides basic research based on the many hypotheses raised, new unbiased epidemiological, clinical, histopathological, natural history, and therapeutic data are clearly needed. They should be confronted by genetics and other investigative variables to better define the disease and its subsets. We hope that the combined efforts of all participating authors...
will prove useful to bring more attention to this field, and we are confident that both the research community (the mystery of melanocyte loss in vitiligo is a true scientific challenge) and the drug industry (the potential market is large) will be stimulated to bring in new treatment strategies to this large number of patients with unmet needs.

Alain Taïeb
Bordeaux, France

Mauro Picardo
Rome, Italy
Section 1: Defining the Disease

1.1 Historical Aspects .......................................................... 3
Yvon Gauthier and Laila Benzekri

1.2 Clinical Overview .......................................................... 11

1.2.1 Epidemiology, Definitions and Classification ..................... 13
Alain Taïeb and Mauro Picardo

1.2.2 Histopathology .......................................................... 25
Flávia Pretti Aslanian, Absalom Figueira,
Tullia Cuzzi, and Béatrice Vergier

1.3 Clinical Aspects ............................................................. 33

1.3.1 Generalized Vitiligo ...................................................... 35
Thierry Passeron and Jean-Paul Ortonne

1.3.2 Segmental Vitiligo ....................................................... 41
Seung-Kyung Hann, Yvon Gauthier, and Laila Benzekri

1.3.3 Vitiligo Universalis ...................................................... 51
Prasad Kumarasinghe

1.3.4 Mucosal Vitiligo ......................................................... 57
Davinder Parsad

1.3.5 Halo Nevi and Vitiligo ................................................... 61
Thomas Jouary and Alain Taïeb

1.3.6 Hair Involvement in Vitiligo .......................................... 65
Rafael Falabella

1.3.7 Non-Skin Melanocytes in Vitiligo ................................... 73
Raymond E. Boissy
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.3.8</td>
<td>Autoimmune/Inflammatory and Other Diseases Associated with Vitiligo</td>
<td>Ilse Mollet, Nanny van Geel, and Jo Lambert</td>
<td>79</td>
</tr>
<tr>
<td>1.3.9</td>
<td>Vitiligo and Immunodeficiencies</td>
<td>Khaled Ezzedine, Sébastien Lepreux, and Alain Taïeb</td>
<td>91</td>
</tr>
<tr>
<td>1.3.10</td>
<td>Inflammatory Vitiligo</td>
<td>Khaled Ezzedine, Julien Seneschal, Ratnam Attili, and Alain Taïeb</td>
<td>99</td>
</tr>
<tr>
<td>1.3.11</td>
<td>Rare Inherited Diseases and Vitiligo</td>
<td>Alain Taïeb and Fanny Morice-Picard</td>
<td>107</td>
</tr>
<tr>
<td>1.3.12</td>
<td>Vitiligo in Childhood</td>
<td>Juliette Mazereeuw-Hautier and Alain Taïeb</td>
<td>117</td>
</tr>
<tr>
<td>1.3.13</td>
<td>Late-Onset Vitiligo</td>
<td>Davinder Parsad and Dipankar De</td>
<td>123</td>
</tr>
<tr>
<td>1.4</td>
<td>Evaluation, Assessment and Scoring</td>
<td>Alain Taïeb and Mauro Picardo</td>
<td>127</td>
</tr>
<tr>
<td>1.5</td>
<td>Quality of Life</td>
<td>Davinder Parsad</td>
<td>135</td>
</tr>
<tr>
<td>1.6</td>
<td>Natural History and Prognosis</td>
<td>Davinder Parsad</td>
<td>139</td>
</tr>
<tr>
<td>1.7</td>
<td>Defining the Disease: Editor’s Synthesis</td>
<td>Alain Taïeb and Mauro Picardo</td>
<td>143</td>
</tr>
<tr>
<td></td>
<td><strong>Section 2: Understanding the Disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1</td>
<td>Pathophysiology Overview</td>
<td>Mauro Picardo and Alain Taïeb</td>
<td>149</td>
</tr>
<tr>
<td>2.2</td>
<td>Generalized Vitiligo</td>
<td></td>
<td>153</td>
</tr>
<tr>
<td>2.2.1</td>
<td>Genetics</td>
<td>Richard Spritz</td>
<td>155</td>
</tr>
<tr>
<td>2.2.2</td>
<td>Environmental Factors</td>
<td></td>
<td>165</td>
</tr>
<tr>
<td>2.2.2.1</td>
<td>The Kobner’s Phenomenon</td>
<td>Yvon Gauthier and Laila Benzekri</td>
<td>167</td>
</tr>
<tr>
<td>2.2.2.2</td>
<td>Occupational Vitiligo</td>
<td>Raymond E. Boissy</td>
<td>175</td>
</tr>
<tr>
<td>2.2.3</td>
<td>In Vivo Data</td>
<td></td>
<td>181</td>
</tr>
</tbody>
</table>
2.2.3.1 Non-Invasive Methods for Vitiligo Evaluation ..................... 183
Marco Ardigò, Francesca Muzio, Mauro Picardo, and Valeria Brazzelli

2.2.3.2 Electron Microscopy .................................................. 197
Yvon Gauthier

2.2.4 Animal Models .............................................................. 205
Gisela F. Erf

2.2.5 In Vitro Approaches ....................................................... 219
Muriel Cario-André and Maria Lucia Dell’Anna

2.2.6 Oxidative Stress ............................................................. 231
Mauro Picardo and Maria Lucia Dell’Anna

2.2.7 Immune/Inflammatory Aspects ........................................ 239

2.2.7.1 Introduction ............................................................... 239
Alain Taïeb

2.2.7.2 The Role of Innate Immunity in Vitiligo ......................... 240
Anna Peroni and Giampiero Girolomoni

2.2.7.3 Humoral Immunity ...................................................... 248
E. Helen Kemp, Anthony P. Weetman, and David J. Gawkrodger

2.2.7.4 Cell-Mediated Immunity .............................................. 256
I. Caroline Le Poole and David A. Norris

2.2.8 Cytokines and Growth Factors ........................................ 269
Genji Imokawa and Silvia Moretti

2.2.9 Proopiomelanocortin and Related Hormones ....................... 283
Markus Böhm

2.2.10 Other Hypotheses .......................................................... 291
Mauro Picardo

2.3 Segmental Vitiligo: A Model to Understand Vitiligo? .............. 295

2.3.1 Particular Clinical Characteristics of Segmental Vitiligo .......... 296
Seung-Kyung Hann

2.3.2 The Concept of Mosaicism Applied to SV ......................... 298
Alain Taïeb

2.3.3 The Neurogenic Hypothesis in Segmental Vitiligo ............... 302
Yvon Gauthier and Laila Benzekri
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.7</td>
<td>Surgical Therapies</td>
<td>393</td>
</tr>
<tr>
<td>3.7.1</td>
<td>Background and Techniques</td>
<td>395</td>
</tr>
<tr>
<td></td>
<td>Mats J. Olsson</td>
<td></td>
</tr>
<tr>
<td>3.7.2</td>
<td>The Outcomes: Lessons About Surgical Therapy for Vitiligo in the Past Two Decades</td>
<td>409</td>
</tr>
<tr>
<td></td>
<td>Rafael Falabella</td>
<td></td>
</tr>
<tr>
<td>3.8</td>
<td>Combined Therapies for Vitiligo</td>
<td>417</td>
</tr>
<tr>
<td></td>
<td>Thierry Passeron and Jean-Paul Ortonne</td>
<td></td>
</tr>
<tr>
<td>3.9</td>
<td>Camouflage</td>
<td>423</td>
</tr>
<tr>
<td></td>
<td>Alida de Pase and Thomas Jouary</td>
<td></td>
</tr>
<tr>
<td>3.10</td>
<td>Photoprotection Issues</td>
<td>431</td>
</tr>
<tr>
<td></td>
<td>Alessia Pacifico, Giovanni Leone and Mauro Picardo</td>
<td></td>
</tr>
<tr>
<td>3.11</td>
<td>Depigmenting Agents</td>
<td>439</td>
</tr>
<tr>
<td></td>
<td>Mauro Picardo and Maria Lucia Dell’Anna</td>
<td></td>
</tr>
<tr>
<td>3.12</td>
<td>Therapy Adapted for Age, Gender, and Specific Locations</td>
<td>443</td>
</tr>
<tr>
<td></td>
<td>Alain Taïeb and Inka Nieuweboer-Krobotova</td>
<td></td>
</tr>
<tr>
<td>3.13</td>
<td>Psychological Interventions</td>
<td>447</td>
</tr>
<tr>
<td></td>
<td>Panagiota Kostopoulou and Alain Taïeb</td>
<td></td>
</tr>
<tr>
<td>3.14</td>
<td>The Patient Perspective</td>
<td>451</td>
</tr>
<tr>
<td></td>
<td>Maxine E. Whitton and Alida DePase</td>
<td></td>
</tr>
<tr>
<td>3.15</td>
<td>Evidence-Based Medicine Perspective</td>
<td>461</td>
</tr>
<tr>
<td></td>
<td>Jean-Paul Ortonne, Thierry Passeron, DJ Gawkrodger, Davinder Prasad, and Somesh Gupta</td>
<td></td>
</tr>
<tr>
<td>3.16</td>
<td>Editor’s Synthesis and Perspectives</td>
<td>471</td>
</tr>
<tr>
<td></td>
<td>Alain Taïeb and Mauro Picardo</td>
<td></td>
</tr>
</tbody>
</table>
Contributors

A. Alomar, M.D  Department of Dermatology; Respiratory Medicine, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
aalomar@santpau.es

Flávia Pretti Aslanian M.D, Ph.D  Federal University of Rio de Janeiro, Rio de Janeiro, Brasil
fpretti@cyberwal.com.br

Marco Ardigò, M.D  San Gallicano Dermatological Institute, IRCCS, Rome, Italy
ardigo@ifo.it

Ratnam Attili  Visakha Institute of Skin and Allergy, Visakhapatnam, India
vrattili@hotmail.com

Laila Benzekri, M.D, Ph.D  Department of Dermatology, CHU Ibn Sina, Rabat, Maroc
lbenzekri2005@yahoo.fr

Markus Böhm, M.D  Department of Dermatology, University of Münster, Münster, Germany
bohmm@uni-muenster.de

Raymond E. Boissy, Ph.D  University of Cincinnati College of Medicine, Cincinnati, OH, USA,
boissy.raymond@uc.edu

Barbara Boone, Ph.D  Department of Dermatology, University Hospital of Ghent, Ghent, Belgium
barbara.boone@ugent.be

Valeria Brazzelli, M.D  Institute of Dermatology, University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
vbrazzelli@libero.it

Muriel Cario-André, Ph.D  Inseri U876, Centre de référence des maladies rares de la peau, Université V Segalen Bordeaux 2, Bordeaux, France
muriel.cario-andre@dermatol.u-bordeaux2.fr

Tullia Cuzzi M.D. Ph.D  Federal University of Rio de Janeiro, Rio de Janeiro, Brasil
tullia@terra.com.br
Maria Lucia Dell’Anna, M.D  Laboratory of Cutaneous Physiopathology, San Gallicano Dermatological Institute IFO, Rome, Italy
citolab@ifo.it

Alida DePase,  Associazione Ricerca Informazione per la Vitiligine (ARIV), Cernusco Lombardone (LC), Italy
depase@arivonlus.it

Dipankar De, M.D  Department of Dermatology, Postgraduate Institute of Medical Education and Research, India
chhinu75@yahoo.co.in

Gisela F. Erf, M.D  Center of Excellence for Poultry Science, University of Arkansas, Fayetteville, Arkansas, USA
gferf@uark.edu

Khaled Ezzedine, M.D, Ph.D.  Service de dermatologie, Hôpital St André, CHU de Bordeaux, France
khaled.ezzedine@chu-bordeaux.fr

Rafael Falabella, M.D  Universidad del Valle and Centro Medico Imbanaco, Cali, Colombia
rfalabella@uniweb.net.co

Absalom Lima Filgueira M.D, Ph.D  Department of Dermatology, Federal University of Rio de Janeiro, Leblon, Rio de Janeiro, Brasil
absalom@uol.com.br

Yvon Gauthier, M.D  Service de Dermatologie, Hôpital Saint-André, CHU de Bordeaux, France
yvongauthier@free.fr

DJ Gawkrodger, M.D  Department of Dermatology, Royal Hallamshire Hospital, Sheffield, UK
david.gawkrodger@sth.nhs.uk

Giampiero Girolomoni, M.D  Clinica Dermatologica, Università di Verona, Verona, Italy.
Giampiero.girolomoni@univr.it

Somesh Gupta, M.D  Department of Dermatology and Venereology, All India Institute of Medical Science, New Delhi, India
someshgupta@hotmail.com

Seung-Kyung Hann, M.D  Korea Institute of Vitiligo Research, Drs. Woo & Han’s skin clinic, Yongsan-Gu, Seoul, South Korea
skhann@paran.com

Genji Imokawa Ph.D  Tokyo University of Technology, School of Bioscience and Biotechnology, Tokyo, Japan
imokawag@dream.ocn.ne.jp
Thomas Jouary, M.D  Service de Dermatologie, Hôpital Saint André, CHU de Bordeaux, France
thomas.jouary@chu-bordeaux.fr

E. Helen Kemp, Ph.D  School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
e.h.kemp@sheffield.ac.uk

Panagiota Kostopoulou, M.D  Service de Dermatologie, Hôpital St André, CHU de Bordeaux, France

Prasad Kumarasinghe, M.D  Consultant Dermatologist, Department of Dermatology, Royal Perth Hospitalm, Western Australia, Australia
prasadkumarasinghe@yahoo.com

Cheng-Che Eric Lan  Department of Dermatology, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd, Kaohsiung, Taiwan
laneric@kmu.edu.tw

Jo Lambert, M.D  Department of Dermatology, Ghent University Hospital, Ghent, Belgium
jo.lambert@ugent.be

Giovanni Leone, M.D  Phototherapy Unit, San Gallicano Dermatological Institute, IFO, Rome, Italy
gleone@ifo.it

I. Caroline Le Poole Ph.D  Loyola University Chicago, Maywood, Illinois
ilepool@lumc.edu

Sébastien Lepreux  Department of Pathology, Hôpital Pellegrin, CHU de Bordeaux, France
sebastien.lepreux@chu-bordeaux.fr

Torello M. Lotti, M.D  Department of Dermatology, University of Florence, Florence, Italy
torello.lotti@unifi.it

Juliette Mazereeuw-Hautier, M.D  Service de Dermatologie, CHU Purpan, Toulouse, France
mazereeuw-hautier.j@chu-toulouse.fr

Ilse Mollet, M.D  Department of Dermatology, Ghent University Hospital, Ghent, Belgium
ilse.mollet@ugent.be

Silvia Moretti, M.D  Department of Dermatological Sciences, University of Florence, Florence, Italy
silvia.moretti@unifi.it

Fanny Morice-Picard, M.D  Departments of Medical Genetics and Dermatology, Hôpital Pellegrin-Enfants, Bordeaux, France
fanny.morice@free.fr
Francesca Muzio, M.D  Department of Human and Hereditary Pathology, Institute of Dermatology, University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy

L. Nieuweboer-Krobotova, M.D  Netherlands Institute for Pigment Disorders, and Department of Dermatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

David A. Norris, M.D  Department of Dermatology, University of Colorado
Denver School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA
david.norris@uchsc.edu

Mats J. Olsson, M.D  Department of Medical Sciences, Dermatology and Venereology, Uppsala University, Sweden
mats.olsson@medsci.uu.se

Jean-Paul Ortonne, M.D  Department of Dermatology, Archet-2 hospital, Nice, France
Jean-Paul.ORTONNE@unice.fr

Alessia Pacifico, M.D  Phototherapy Unit, San Gallicano Dermatological Institute, IFO, Rome, Italy
alessia.pacifico@tiscali.it

Davinder Parsad, M.D  Department of Dermatology, Postgraduate Institute of Medical Education & Research, Chandigarh, India
parsad@mac.com

Thierry Passeron, M.D, Ph.D  Department of Dermatology, University Hospital of Nice, Nice, France
passeron@unice.fr

Anna Peroni, M.D  Dermatological Clinic, University of Verona, Verona, Italy
anna.peroni@univr.it

Mauro Picardo, M.D  Laboratory of Cutaneous Physiopathology, San Gallicano Dermatological Institute, IFO, Via San Gallicano, 25, 00153 Rome, Italy
picardo@ifo.it

Julien Seneschal, M.D  Service de dermatologie, Hôpital St André, CHU de Bordeaux, France
julien.seneschal@free.fr

Richard Spritz, M.D  Human Medical Genetics Program, University of Colorado
Denver, Aurora, Colorado, USA
richard.spritz@uchsc.edu

Alain Taieb, M.D  Service de Dermatologie, Hôpital St André, CHU de Bordeaux, France
alain.taieb@chu-bordeaux.fr

Adrian Tanew, M.D  Phototherapy Unit, Division of Special and Environmental Dermatology, Medical University of Vienna, Vienna, Austria
adrian.tanew@meduniwien.ac.at
J.P.W. van der Veen, M.D  Netherlands Institute for Pigment Disorders, and Department of Dermatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
j.p.vanderveen@amc.uva.nl

Nanny Van Geel, M.D  Department of Dermatology, Ghent University Hospital, Ghent, Belgium
nanny.vangeel@ugent.be

Béatrice Vergier, M.D  Department of Pathology, Hôpital du Haut Lévêque, Bordeaux, France
beatrice.vergier@chu-bordeaux.fr

Bas S. Wind  Netherlands Institute for Pigment Disorders, and Department of Dermatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

Maxine Eloise Whitton  Wanstead, UK
mewhitton@aol.com

Ching-Shuang Wu  Faculty of Biomedical Laboratory Science, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd, Kaohsiung, Taiwan
m785034@kmu.edu.tw

Hsin-Su Yu  Department of Dermatology, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd, Kaohsiung, Taiwan
dermyu@kmu.edu.tw